Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival

Table 2 Univariate and multivariate predictors of overall survival > 12 mo among patients with malignancy using immune checkpoint inhibitor (n = 128)

Clinical variables	Univariate predictors			Multivariate predictors
	OR	95%CI	P value	OR	95%CI	P value
Demographics
Age (yr)	1.00	0.97-1.03	0.970
Male	0.92	0.45-1.87	0.822
Female	1.08	0.53-2.20	0.822
Race
White	1.37	0.58-3.25	0.473
Black	2.39	0.24-23.6	0.456
Asian	0.97	0.25-3.79	0.965
Other	0.45	0.14-1.45	0.181
Type of malignancy
Melanoma	0.87	0.43-1.74	0.688
RCC	1.65	0.53-5.12	0.390
NSCLC	2.52	0.65-9.80	0.181
Sarcoma	0.15	0.03-0.72	0.018	0.17	0.03-0.95	0.043
Head and neck SCC	1.04	0.22-4.84	0.961
Other	1.50	0.52-4.35	0.453
Presence of IMC	2.16	1.06-4.41	0.034	2.81	1.17-6.77	0.021
Presence of high grade IMC	0.47	0.16-1.38	0.167
Stage IV malignancy	0.48	0.14-1.61	0.233
Type of Immune Checkpoint Inhibitor
Ipilimumab plus nivolumab	1.32	0.30-5.77	0.714
Ipilimumab	0.74	0.29-1.85	0.517
Nivolumab	1.63	0.46-5.70	0.448
Pembrolizumab	2.93	1.27-6.73	0.011	1.06	0.38-2.98	0.911
Atezolizumab	1.32	0.30-5.77	0.714
Number of ICI infusionsa	1.19	1.08-1.32	0.001	1.23	1.09-1.40	0.001
Dose of ICI (mg/kg)	1.33	0.86-2.05	0.198
Prior ICI use	0.51	0.19-1.37	0.183
Medical history
Non-liver, non-upper GI diseaseb	0.87	0.38-2.02	0.747
Personal history of autoimmune diseaseb	1.47	0.63-3.40	0.373
Family history of autoimmune diseaseb	1.03	0.32-4.41	0.804
Prior irAE	2.84	0.31 - 25.9	0.356
Prior immune-enhancing therapyb	0.62	0.18-2.15	0.454
Vitamin D use	0.60	0.28-1.29	0.190
Smoking (current or prior)	0.74	0.37-1.50	0.410
NSAID use	1.04	0.41-2.69	0.928
Any vaccine	0.36	0.14-0.89	0.026	1.03	0.16-6.70	0.972
Flu vaccine	0.22	0.08-0.67	0.007	0.30	0.04-2.31	0.248
Pneumonia vaccine	0.41	0.11-1.48	0.175
Other vaccine	0.77	0.05-12.66	0.858
Weight at start of ICI (kg)	0.99	0.97-1.01	0.207
Medications
Steroid at start of ICI	0.74	0.29-1.93	0.541
Steroid duration (d)	1.00	0.997-1.01	0.368
Infliximab use	0.76	0.21-2.77	0.226
Vedolizumab use	1.00	0.99-1.01	1.000

^aNumber of infusions of immune checkpoint inhibitor prior to immune checkpoint inhibitor-mediated colitis diagnosis (cases) or total (controls).

^bSee Supplementary Table 2.

ICI: Immune checkpoint inhibitor; IMC: Immune checkpoint inhibitor-mediated colitis; OR: Odds ratios; CI: Confidence interval; SD: Standard deviation; RCC: Renal cell carcinoma; NSCLC: Non-small cell lung cancer; SCC: Squamous cell carcinoma; irAE: Immune related adverse event.